Company News
Your source for the latest company news, including updates, achievements, and milestones. Explore our press releases, announcements, and event highlights to stay informed about our progress and contributions to advancing drug development and manufacturing.
News
Your source for the latest updates, breakthroughs, and insights in drug development and manufacturing. Explore our featured stories, press releases, and event announcements to stay informed about our innovations and contributions to drug development and manufacturing advancements.
American Society of Gene & Cell Therapy (ASGCT) Annual Meeting – 2025
Avance Biosciences is excited to exhibit at the ASGCT 2025 conference in New Orleans, LA, from May 13–17, 2025. Join us to explore our expert bioanalytical solutions for gene and cell therapy development. Visit booth #750 to learn how we can support your therapeutic advancements...
American Assoc. of Pharmaceutical Scientists (AAPS) National Biotechnology Conference – 2025
Avance Biosciences™ is joining the 2025 AAPS National Biotechnology Conference to showcase our expertise in biological assay development, validation, and sample testing. Visit our booth to learn more about our innovative solutions and explore potential collaborations in drug development...
World Vaccine Congress – 2025
Avance Biosciences is excited to participate in the World Vaccine Congress 2025, showcasing our advanced solutions in vaccine development, bioanalytics, and regulatory compliance. Join us to explore collaboration opportunities and learn how our services can support your vaccine research and clinical trials...
Workshops on Recent Issues in Bioanalysis (WRIB) – 2025
Avance Biosciences is excited to join WRIB 2025 in New Orleans, showcasing our expertise in bioanalytical testing for biologics and biosimilars. Visit us at Booth #78 to explore our advanced solutions, including LBA, Flow Cytometry, qPCR, and LC-MS/MS. [...]
Avance Biosciences Plays Key Role in RNA Sequencing for Promising COVID-19 Vaccine
Avance Biosciences contributed critical RNA sequencing to the development of MV-014-212, a novel intranasal COVID-19 vaccine. In preclinical trials, MV-014-212 showed significant promise by reducing viral shedding and eliciting a broad immune response, including protection against multiple variants of concern...
Empowering Drug Development with CLIA Testing Services
Avance Biosciences offers CLIA-compliant testing services to ensure accurate, reliable data throughout drug development. From biomarker validation to regulatory support, our expertise helps biopharmaceutical companies advance clinical trials and bring innovative biologic treatments to market with confidence...
